Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.
|ジャーナル||Japanese Journal of Cancer and Chemotherapy|
|出版ステータス||Published - 04-2018|
All Science Journal Classification (ASJC) codes